Press release Biocartis Group NV: Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed
15 Juni 2022 - 7:00AM
Press release Biocartis Group NV: Biocartis Reaches Key Commercial
Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th
Idylla™ Instrument Placed
PRESS RELEASE: 15 June 2022, 07:00 CEST
Biocartis Reaches
Key Commercial
Milestones: One-Millionth
Idylla™ Cartridge
Sold
and 2,000th
Idylla™ Instrument Placed
Mechelen, Belgium,
15 June
2022 – Biocartis
Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular
diagnostics company (Euronext Brussels: BCART), announces a double
milestone today: the selling of its one-millionth commercial
Idylla™ cartridge and the placement of its 2,000th Idylla™
instrument since its commercial launch. These events mark a key
commercial milestone for Biocartis, which has been commercializing
its rapid and easy-to-use decentralized Idylla™ molecular
diagnostics platform in more than 70 countries across the world
since 2015.
Biocartis launched its first commercial
products, the Idylla™ instrument and the Idylla™ BRAF Mutation Test
(CE-IVD), in the European market in September 2014, following their
CE-IVD marking. Today, over 125 publications have been issued
worldwide supporting the scientific validation and performance of
the Idylla™ platform. The platform is differentiated by its simple,
fast and highly accurate decentralized delivery of molecular
diagnostic results that enables fast access to the right treatment
for patients across the globe.
With a focus on oncology, Biocartis’ current
Idylla™ menu strategy covers the entire continuum of cancer care -
from prognosis to surveillance - with a broad on-market menu of
tests in melanoma, lung and colorectal cancer which aim to better
inform clinical decisions being made by healthcare providers for
their oncology patients. Biocartis is also increasingly leveraging
innovative biomarker content with partners that aim to roll out
their test content globally on Idylla™. Thanks to the support of an
expanding partner community, Biocartis aims to expand in breast,
thyroid, hematology and brain cancers, as well as growing its
offering into infectious diseases. The success of the platform has
led to a strong 42% increase in oncology cartridge revenue in Q1
2022 compared to Q1 2021.
Herman Verrelst, Chief Executive Officer
of Biocartis, reacted: “We are very proud
of these milestones and the entire Biocartis team who has
diligently built this transformative Idylla™ technology into a
platform that contributes to provide patients with a better quality
of life. The 2,000th instrument placement confirms that we have one
of the largest decentralized installed bases globally in oncology
molecular diagnostics. Since 2016, we have built a strong
commercial franchise, growing revenues from instrument placements
and cartridge sales by approximately 44% per year, while positively
impacting the lives of many patients and their families. The
milestones we announce today demonstrates our success in building
critical mass and our readiness to scale.”
--- END ---
More information: Renate
DegraveHead of Corporate Communications & Investor Relations
Biocartise-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an
innovative molecular diagnostics (MDx) company providing next
generation diagnostic solutions aimed at improving clinical
practice for the benefit of patients, clinicians, payers and
industry. Biocartis' proprietary MDx Idylla™ platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain
Reaction) system that offers accurate, highly reliable molecular
information from virtually any biological sample in virtually any
setting. Biocartis is developing and marketing a continuously
expanding test menu addressing key unmet clinical needs, with a
focus in oncology, which represents the fastest growing segment of
the MDx market worldwide. Today, Biocartis offers tests supporting
melanoma, colorectal and lung cancer, as well as for COVID-19, flu,
RSV and sepsis. More information: www.biocartis.com. Follow us
on Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product. This press release is not
for distribution, directly or indirectly, in any jurisdiction where
to do so would be unlawful. Any persons reading this press release
should inform themselves of and observe any such restrictions.
Biocartis takes no responsibility for any violation of any such
restrictions by any person. This press release does not constitute
an offer or invitation for the sale or purchase of securities in
any jurisdiction. No securities of Biocartis may be offered or sold
in the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Biocartis Group NV (EU:BCART)
Historical Stock Chart
Von Apr 2023 bis Apr 2024